WuXi Biologics (Cayman) Inc
HKEX:2269
WuXi Biologics (Cayman) Inc
Operating Income
WuXi Biologics (Cayman) Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Operating Income
¥4.4B
|
CAGR 3-Years
39%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Operating Income
¥11.5B
|
CAGR 3-Years
52%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Operating Income
¥1.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Operating Income
¥1.7B
|
CAGR 3-Years
21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
34%
|
|
Genscript Biotech Corp
HKEX:1548
|
Operating Income
-$314.2m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Operating Income
¥190.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is WuXi Biologics (Cayman) Inc's Operating Income?
Operating Income
4.4B
CNY
Based on the financial report for Dec 31, 2023, WuXi Biologics (Cayman) Inc's Operating Income amounts to 4.4B CNY.
What is WuXi Biologics (Cayman) Inc's Operating Income growth rate?
Operating Income CAGR 5Y
45%
Over the last year, the Operating Income growth was -3%. The average annual Operating Income growth rates for WuXi Biologics (Cayman) Inc have been 39% over the past three years , 45% over the past five years .